Nippon Shinyaku Co., Ltd. 4516
TSE · Japan · Health Technology
¥3,497.00+55.00 (+1.60%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
NS Pharma, Inc. (Headquarters: Paramus, New Jersey; President: Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan; President: Toru Nakai), has exercised its option rights under the option agreement entered into with AB2 BIO Ltd. (Headquarters: Lausanne, Switzerland, CEO: Djordje Filipovic) in January 2025 regarding Tadekinig alfa. Through the exercise of the option rights, Nippon Shinyaku has obtained exclusive commercialization righ
AB2 Bio receives $30 million from Nippon Shinyaku for exclusive U.S. commercialization rights to Tadekinig Alfa Nippon Shinyaku exercises its exclusive U.S. commercialization option for Tadekinig alfa after AB2 Bio’s positive interactions with U.S. FDALicense covers lead indication in the U.S., Primary Monogenic IL-18-Driven Hyperinflammatory Syndrome in patients with NLRC4 and XIAP mutationsAB2 Bio retains world-wide rights to Tadekinig alfa for all other indications and all ex-U.S. rights for
NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto, Japan; President, Toru Nakai) has entered into an option agreement with Elixirgen Therapeutics, Inc. (Elixirgen; Headquarters, Baltimore, MD; CEO, Aki Ko) under which Nippon Shinyaku may obtain the exclusive worldwide rights to develop and commercialize EXG-7001 for the treatment of Duchenne muscular dystrop
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.